Annual Report

Overview

The report presents Sumitomo Dainippon Pharma's operational and financial performance for fiscal 2014 (ended March 31, 2015). The Group recorded consolidated net sales of ¥371.4 billion and operating income of ¥23.3 billion, impacted by Japanese drug price revisions while benefiting from North American LATUDA® growth. Strategic R&D efforts focused on psychiatry, neurology, and oncology, including global Phase III trials. Environmental initiatives achieved a reduction in CO2 emissions to 72,981 tonnes, representing an 11% decrease compared to FY2005 levels.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2014-2015
Period: 1 April 2014 – 31 March 2015
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Ratings

GRI level

Materiality

Assessment
Basis

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services